More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$20.31B
EPS
8.52
P/E ratio
21.4
Price to sales
1.87
Dividend yield
1.753%
Beta
0.619004
Previous close
$181.57
Today's open
$182.16
Day's range
$181.23 - $183.01
52 week range
$148.70 - $197.55
show more
CEO
James E. Davis
Employees
56000
Headquarters
Secaucus, NJ
Exchange
New York Stock Exchange
Shares outstanding
111242362
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Dec 12, 2025

Digi Power X Inc. (DGX:CA) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Digi Power X Inc. (DGX:CA) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Seeking Alpha • Dec 9, 2025

Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Seeking Alpha • Dec 2, 2025

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Dec 1, 2025

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States
MENLO PARK, Calif.--(BUSINESS WIRE)-- #MSCare--Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson's disease, today announced a strategic collaboration with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, to make the OctaveⓇ Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest's nationwide specimen-collection network. Prov.
Business Wire • Dec 1, 2025

HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet?
DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.
Zacks Investment Research • Nov 27, 2025

Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research • Nov 26, 2025

Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?
DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.
Zacks Investment Research • Nov 24, 2025

Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Nov 20, 2025

Quest Diagnostics Incorporated (DGX) Presents at 7th Annual Healthcare Symposium Transcript
Quest Diagnostics Incorporated ( DGX ) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants Asia Chang Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. Carri Chan David Harding Noam Krantz - Guardant Health, Inc. Alexis Tosti Presentation Kevin Dreyer GAMCO Investors, Inc. Okay. I want to welcome everyone to our 7th Annual Healthcare Symposium jointly sponsored by Gabelli Funds and Columbia Business School.
Seeking Alpha • Nov 14, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Quest Diagnostics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.